Vericel (NASDAQ:VCEL) Stock Lifted to Strong-Buy by Zacks Research

by · The Cerbat Gem

Vericel (NASDAQ:VCEL – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday, Zacks reports.

Other research analysts have also issued reports about the stock. HC Wainwright raised their price target on shares of Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. TD Cowen boosted their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Truist Financial increased their target price on Vericel from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday. Finally, Stephens raised their target price on Vericel from $55.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Vericel currently has an average rating of “Buy” and an average target price of $62.00.

View Our Latest Analysis on VCEL

Vericel Stock Performance

NASDAQ:VCEL opened at $59.03 on Monday. The company has a fifty day moving average of $41.74 and a two-hundred day moving average of $39.10. The stock has a market capitalization of $3.01 billion, a PE ratio of 91.23 and a beta of 1.08. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $59.72.

Vericel (NASDAQ:VCEL – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The business had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. During the same period last year, the firm posted $0.10 earnings per share. The company’s revenue was up 26.5% compared to the same quarter last year. Research analysts forecast that Vericel will post 0.73 earnings per share for the current year.

Insider Activity

In related news, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $51.92, for a total transaction of $778,800.00. Following the transaction, the insider directly owned 1,990 shares in the company, valued at approximately $103,320.80. The trade was a 88.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Siegal sold 1,500 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $52.90, for a total transaction of $79,350.00. Following the sale, the insider directly owned 1,259 shares of the company’s stock, valued at approximately $66,601.10. This represents a 54.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 22,000 shares of company stock worth $1,128,340 over the last three months. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hantz Financial Services Inc. increased its holdings in shares of Vericel by 24.8% in the third quarter. Hantz Financial Services Inc. now owns 1,194 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 237 shares during the last quarter. GAMMA Investing LLC lifted its position in Vericel by 17.7% during the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock worth $84,000 after buying an additional 283 shares in the last quarter. Kopp Family Office LLC boosted its stake in Vericel by 0.6% during the third quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock worth $2,061,000 after buying an additional 299 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Vericel by 0.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 157,081 shares of the biotechnology company’s stock worth $6,195,000 after buying an additional 435 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in Vericel by 2.2% in the 2nd quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock valued at $1,027,000 after buying an additional 500 shares in the last quarter.

Key Stories Impacting Vericel

Here are the key news stories impacting Vericel this week:

  • Positive Sentiment: Stephens raised its price target to $68 from $55 and reiterated an “Overweight” rating, signaling confidence in further upside. Stephens rating information
  • Positive Sentiment: HC Wainwright lifted its estimates, including FY2026 EPS to $0.79 from $0.45 and FY2027 EPS to $0.89 from $0.68. The firm maintains a “Buy” rating and a $75 price target. Vericel analyst estimates
  • Positive Sentiment: Zacks also cited improving earnings-estimate revisions as a reason Vericel shares may continue gaining, adding to the constructive analyst outlook. Zacks article
  • Neutral Sentiment: A report described a significant increase in short interest but listed total short interest as zero shares, so the figures do not provide a clear signal about bearish positioning.
  • Neutral Sentiment: Vericel published its 2026 third-quarter earnings-call presentation; the article listing provided no specific new financial details. Earnings call presentation

Vericel Company Profile

(Get Free Report)

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

Featured Stories